Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$33.72 USD
+0.70 (2.12%)
Updated Aug 4, 2025 04:00 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCVX 33.72 +0.70(2.12%)
Will PCVX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCVX
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Other News for PCVX
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
TimesSquare U.S. Small Cap Growth Strategy Q2 2025 Commentary
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc.
Vaxcyte (PCVX) Maintains Strength Amid Potential Vaccine Review | PCVX Stock News
Vaxcyte vaccine candidates contain aluminum, says Mizuho